abiraterone has been researched along with Hormone-Dependent Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 18 (78.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hartmann, RW; Hille, UE; Hu, Q; Jagusch, C; Yin, L | 1 |
| Agarwal, N; Hahn, AW; Hale, P; Rathi, N | 1 |
| Dowsett, M; Folkerd, E; Johnston, SR; Liccardi, G; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N | 1 |
| Kretschmer, A; Todenhöfer, T | 1 |
| Halabi, S; Parelukar, WR; Rydzewska, L; Tierney, JF; Vale, CL | 1 |
| Arlen, PM; Madan, RA | 1 |
| Bossi, P; Civelli, E; Cortelazzi, B; Imbimbo, M; Licitra, L; Locati, LD; Perrone, F; Pilotti, S; Potepan, P; Quattrone, P; Rinaldi, G | 1 |
| Aebersold, D; Attard, G; Cassoly, E; Clarke, NW; de Bono, JS; Dearnaley, DP; James, ND; Mason, MD; Matheson, D; Millman, R; Parker, CC; Parmar, MK; Ritchie, AW; Russell, JM; Schiavone, F; Spears, MR; Sydes, MR; Thalmann, G | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Klein, EA; Raghavan, D | 1 |
| Attard, G; Barrett, M; Clark, J; Cooper, CS; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Lee, G; Martins, V; Parker, C; Raynaud, F; Reid, AH; Settatree, S; Yap, TA | 1 |
| Ang, JE; de Bono, JS; Olmos, D | 1 |
| A'Hern, R; Attard, G; Carden, CP; Cooper, CS; Coumans, F; Cox, ME; de Bono, JS; Dearnaley, D; Hawche, G; Jameson, C; Kaye, SB; Levink, R; Molina, A; Moreira, J; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Riisnaes, R; Sipkema, R; Swennenhuis, JF; Terstappen, LW; Thompson, E; Vickers, E | 1 |
| A'Hern, R; Attard, G; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Kheoh, T; Lee, G; Maier, G; Messiou, C; Molife, LR; Molina, A; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Sinha, R; Thompson, E | 1 |
| Raghavan, D; Shepard, DR | 1 |
| Chowdhury, S; Harper, P; Powles, T | 1 |
| Miller, K | 1 |
| Balk, SP; Cai, C | 1 |
| Courtney, KD; Taplin, ME | 1 |
| Bluemn, E; Edwards, J; Gurel, M; Hu, R; Isaacs, WB; Lu, C; Luo, J; Mostaghel, EA; Nelson, PS; Plymate, SR; Tannahill, C; Yegnasubramanian, S | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Cheng, ML; Ryan, CJ | 1 |
10 review(s) available for abiraterone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Humans; Male; Neoplasms, Hormone-Dependent; Patient Selection; Prednisolone; Prednisone; Prostatic Neoplasms; Treatment Outcome | 2017 |
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Recent advances revolutionize treatment of metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Hormone Replacement Therapy; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Tissue Extracts | 2013 |
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Male; Models, Biological; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Failure | 2009 |
Innovations in the systemic therapy of prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Humans; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis | 2010 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
Topics: Androgens; Androstenes; Androstenols; Enzyme Inhibitors; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen | 2011 |
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Thiohydantoins | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
Abiraterone acetate for the treatment of prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Androstenes; Androstenols; Antineoplastic Agents; Castration; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen | 2013 |
3 trial(s) available for abiraterone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytochrome P-450 Enzyme Inhibitors; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms; Research Design; Steroid 17-alpha-Hydroxylase; Switzerland; Treatment Outcome; United Kingdom | 2014 |
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androstenes; Androstenols; Castration; Disease Progression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Treatment Outcome | 2008 |
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2009 |
10 other study(ies) available for abiraterone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Topics: Antineoplastic Agents, Hormonal; Biphenyl Compounds; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Pyridines; Spectrometry, Mass, Electrospray Ionization; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Substrate Specificity | 2010 |
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Topics: Androstenes; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Androgen; Signal Transduction; Tamoxifen | 2018 |
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
Topics: Adenocarcinoma; Adult; Androgen Antagonists; Androstenes; Androstenols; Anilides; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Androgen; Salivary Gland Neoplasms; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2014 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
Prostate cancer: moving forward by reinventing the wheel...but this time it is round.
Topics: Androstenes; Androstenols; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms | 2008 |
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antigens, Neoplasm; Cell Adhesion Molecules; Epithelial Cell Adhesion Molecule; Gene Order; Humans; Immunomagnetic Separation; In Situ Hybridization, Fluorescence; Keratins; Male; Neoplasms, Hormone-Dependent; Neoplastic Cells, Circulating; Oncogene Proteins, Fusion; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Trans-Activators; Transcriptional Regulator ERG | 2009 |
Castration refractory prostate cancer: cinderella finally comes to the ball.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Testosterone; Tissue Extracts | 2010 |
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Animals; Benzamides; Castration; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Mice; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Protein Isoforms; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Transcription, Genetic; Transplantation, Heterologous; Ubiquitin-Conjugating Enzymes | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |